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1. Introduction
Dimensional approach in clinical psychopharmacology conceptualizes a disorder under
multiple dimensions that are affected at a particular time. Impairments in multiple domains
is a major factor leading to the fact that significant proportion of patients with various major
psychiatric disorders does not achieve remission (McEvoy et al., 2006; Perlis et al., 2006; Rush
et al., 2006). This model proposes to tackle each dimension independently as the interaction
between the various dimensions remains to be accurately understood (Baruch et al., 1992).
Such an approach has lead to use of several molecules in the treatment of a single condition,
a situation that we often refer to as polypharmacy. Increasing frequency of polypharmacy
(Mojtabai and Olfson, 2010) suggests that the major approach in pharmacological treatment
of psychiatric disorders is the dimensional one.
Psychiatry being one of the most complex specialties among medicine, psychiatric diagnosis
is based on subjective personal history and specifically constructed clinical criteria. There is a
certain lack of empirical data and more so for objective laboratory tests. Moreover, with the
increasing identification of comorbid conditions and evidence-based guidelines recommend‐
ing an array of molecules in the treatment of a single disorder, without the emphasis on,
preference has escalated the strategy of polypharmacy. The reported overall prevalence rates
of polypharmacy in psychiatry vary between 13% to an alluring 90% (Kukreja et al., 2013).
2. Definition and classification
Although the term polypharmacy has been in use and has evolved for a very long time, a
proper definition is still lacking. Majority of studies in psychiatry have used the criteria of “2
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or more medications of the same chemical class or with the same or similar pharmacological
actions to treat the same condition” (Kukreja et al., 2013). Apart from a trendy yet justifiable
classification of polypharmacy into-“The Good, the Bad, and the Ugly” (Kingsbury and Lotito,
2007), several other classifications have been proposed to describe various types of polyphar‐
macy (Table 1). Multiclass Polypharmacy is the most common type with prevalence of 20.9%
among which combination of SSRI with a benzodiazepine is the most common. In the same
class polypharmacy, treatment with several benzodiazepines is the most common (De las
Cuevas and Sanz, 2004).
The basis for these classifications is discrete and hence there would be significant overlap when
considering them together i.e. combination of lithium and fluoxetine in treating resistant
depression is an example of therapeutic, multiclass, minor and rational polypharmacy. As
positive outcome is the foundation for evidence based treatment, contra-therapeutic and
rational polypharmacy are mutually exclusive. However, with wide inter-individual hetero‐
geneity, one may consider none of the classes to be exclusively inseparable i.e. rational strategy
of clozapine augmentation with olanzapine might result in worsening of metabolic status,
resulting in contra-therapeutic polypharmacy.
Sl.no Classification Basis Proposed by
1 • Therapeutic• Contra-therapeutic Outcome Werder and Preskorn, 2003
2
• Same class
• Multiclass
• Adjunctive
• Augmentative
• Total
Pharmacological class and
appropriateness
National Association of State Mental
Health Program Directors, 2001
3
• Minor
• Moderate
• Major
Number of drugs Veehof et al., 2000
4 • Rational• Irrational Rationality/ evidence base Kingsbury et al., 2001
Table 1. Polypharmacy-several classifications
This narrative review considers various rational polypharmacy strategies in treating psychi‐
atric disorders. Evidence base for polypharmacy strategies in individual disorders is high‐
lighted with an emphasis on special settings.
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3. Depression
Polypharmacy in the treatment of depression has an increasing trend. While 3.3% of depression
patients received 3 or more drugs in 1970s, in 1990s the rate increased to 43.8% in an NIMH
hospital (Frye et al., 2000). Although the exact share of rational polypharmacy could not be
ascertained, evidence base for polypharmacy in depression management is satisfactory.
With a number of molecules with different mechanisms of action available, combination of
any two compounds has a potential for an impressive strategy to treat depression that does
not respond to antidepressant monotherapy (Moret, 2005). Combinations of certain antide‐
pressants-mirtazapine combined with venlafaxine, fluoxetine and bupropion (in the order of
highest response) have been shown to have better response rate than anti depressant mono‐
therapy (fluoxetine plus placebo) (Blier et al., 2010). Blier and colleagues had also found that
a combination of mirtazapine and paroxetine showed significantly higher response rates than
either drug alone (Blier et al., 2009). There has been another study (Carpenter et al., 2002) that
studied a selective serotonin reuptake inhibitor (SSRI) combined with mirtazapine and found
the combination to be better. Nelson et al. (2004) found a combination of fluoxetine and
desipramine to be better than either drug alone. Recently, Sung et al. (2012) compared
escitalopram monotherapy with bupropion+escilatoplram and velnafaxine+mirtazapine and
found that there was no significant difference in the adverse effect profile in both chronic and
non chronic depression patients. However, they found no significant difference in either
response or remission rates between the different treatment groups. Positive data from
controlled trials on antidepressant combinations are restricted to mirtazapine as the combi‐
nation drug questioning the generalizability of the findings to other combinations. Also these
trials are not free of limitations: insufficient duration, lower doses of monotherapy agents, etc.
(Rush, 2010). Trials including other agents like SAM (S-adenosyl-l-methionine) are not
randomized controlled (Alpert et al., 2004).
Various augmentation drugs used in the treatment of depression in combination with an
antidepressant are-atypical antipsychotics, lithium, hormonal drugs like thyroxine, estrogen
and mifepristone, 5HT1A antagonists like pindolol, buspirone, and, stimulants like methyl‐
phenidate. Augmentation with atypical antipsychotics has been shown to be significantly more
effective than placebo for response and remission. Although aripiprazole is the first pharma‐
cologic agent of any type to be approved by the U.S. FDA for use as an augmentation agent in
major depressive disorder, other agents have also been used. Among atypical antipsychotics,
evidence is available for olanzapine in combination with fluoxetine, quetiapine and aripipra‐
zole in combination with either SSRI or an SNRI and risperidone with various antidepressants
(Nelson and Papakostas, 2009). While the meta-Analysis by Nelson and Papakostas (2009)
conclude no significant differences in efficacy among the different agents, Connolly and Thase
(2011) in their review give a preference to quetiapine and aripiprazole. Bauer et al. (2010) in
their meta-analysis found significantly greater mean response rate in the lithium group than
the placebo group. Apart from stating augmentation of antidepressants with lithium as the
best-evidenced augmentation therapy in the treatment of depression, they also suggested a
predictive role of the –50T/C single nucleotide polymorphism of the GSK3-beta gene (Bauer
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et al., 2010). However, Connolly and Thase (2011) question its generalizability stating lithium
is only effective for use in combination with tricyclic antidepressants (TCAs) and that these
trials included less treatment-resistant subjects than those who typically receive TCAs in
current clinical settings. Triiodothyronine augmentation seems to offer better benefit/risk ratio
for augmentation of modern antidepressants (Connolly and Thase, 2011). While trials on
pindolol have failed to replicate positive effects, there is no clear consensus of the role of
buspirone, mifepristone and methylphenidate (Moret, 2005). Although estrogen augmentation
is effective, the response seems to be more restricted to menopausal women (Liu et al., 2004).
Surprisingly however, data from trials on combination of conventional antidepressants like
tricyclic agents and MAO inhibitors or augmentation with first generation antipsychotics is
sparse.
4. Bipolar disorder
4.1. Acute mania
In reality, less than 10% of acutely manic patients receive monotherapy. Clinical routine
appears to be based on polypharmacy in bipolar patients (Peh and Tay 2008). In line with this
clinical practice, RCT’s suggest that addition of an antipsychotic to patients with persistent
manic symptoms despite treatment with lithium or valproate has shown greater rates of acute
efficacy than has continuation of lithium or valproate alone (Vieta et al., 2008). As to the
important clinical question whether de novo combinations are better, there is very limited data.
A greater efficacy of combination treatment is also supported by a meta-analysis of Smith et
al. (2007) which showed that significantly more participants on co-therapy met the response
criterion reductions. Such effects were demonstrated for haloperidol, olanzapine, risperidone
and quetiapine when administered as co-therapy compared with monotherapy with lithium
or valproate. Taken together, there is not enough unambiguous evidence that supports
combination therapy as a general first line treatment (Grunze et al., 2009).
4.2. Acute bipolar depression
In the case of acute bipolar depression, the categories of evidence and grades of recommen‐
dation for pharmacological treatment are mentioned in table 2. Olanzapine+fluoxetine (Tohen
et al. 2003; Brown et al. 2009), Lamotrigine+Lithium (van der Loos et al. 2009), Modafinil
+ongoing treatment (Frye et al. 2007) and N-acetylcysteine+Lithium or Valproate (Berk et al.
2008) have been investigated in controlled studies and have positive evidence. Other combi‐
nations are either not studied under controlled conditions or have shown inconsistent results
(Grunze et al., 2010).
4.3. Bipolar disorder prophylaxis
In routine practice, combination treatments are regularly employed to enhance efficacy of
maintenance treatment and to address sub-syndromal symptoms or functional impairment.
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For example, prospective data of the Stanley Foundation Bipolar Network showed that over
55% of bipolar patients were on two or three medications, 31.8% required four or more drugs
and 13.8% requiring five or more medications, but still it took a mean time of 1.5 years to
achieve a sustained remission (Post et al., 2010). Positive placebo-controlled RCTs exist for
combination treatments of mood stabilizers-valproate+lithium (Geddes et al., 2010), valproate
or lithium, with all atypical antipsychotics that have a license for bipolar maintenance
treatment – aripiprazole (Marcus et al., 2011), quetiapine (Vieta et al.,2008; Suppes et al.,
2009), risperidone (Yatham et al., 2003) and ziprasidone (Bowden et al., 2010). The treatment
of bipolar disorder patients may also change frequently in response to side effects, emerging
comorbidities including physical health issues and other needs to be specifically tailored for
each patient. These needs in real world patients are virtually impossible to capture in a
guideline whose focus is the efficacy of a given combination treatment over a limited time
period and in a fair proportion of patients. These limitations should be kept in mind when
interpreting data of randomized controlled combination maintenance studies. For this reason,
various guidelines do not make a special note or recommendation for specific combination
treatments (Grunze et al., 2013).
Combination and Augmentation
Treatments Category of Evidence
Recommendation
Grade
Olanzapine + Fluoxetine Limited positive evidence from controlled studies 3
Lamotrigine + Lithium Limited positive evidence from controlled studies 3
Modafinil + ongoing treatment Limited positive evidence from controlled studies 3
N-acetylcysteine + Lithium or Valproate Limited positive evidence from controlled studies 3
Sertraline + Lithium or Valproate Evidence from uncontrolled studies 4
Tranylcypromine + ongoing treatment Evidence from uncontrolled studies 4
Venlafaxine + Lithium or Valproate Evidence from uncontrolled studies 4
L-Thyroxine + ongoing treatment Evidence from uncontrolled studies 4
Topiramate + Lithium or Valproate Evidence from uncontrolled studies 4
Zonisamide + Lithium or Valproate Evidence from uncontrolled studies 4
Imipramine + Lithium Inconsistent results 5
Inositol + Lithium or Valproate Inconsistent results 5
Omega 3 fatty acids + Lithium or Valproate Inconsistent results 5
Paroxetine + Lithium or Valproate Inconsistent results 5
Bupropion + Lithium or Valproate Inconsistent results 5
Gabapentin + ongoing treatment Inconsistent results 5
Table 2. Categories of evidence and grades of recommendation for acute bipolar depression (Adapted from Grunze et
al.(2010))
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5. Anxiety disorder
Benzodiazepines are used in combination with serotonergic drugs during the initial phase-a
week or two, before the onset of anti-anxiety effect, either to hasten its efficacy or to suppress
the activating side effects that are seen when serotonergic therapy has been started. In the
treatment of panic disorder, there is persistent positive evidence from randomized controlled
studies for the combination of antidepressants and benzodiazepines (clonazepam plus
paroxetine or sertraline) (Pollack et al. 2003; Goddard et al. 2001). But evidence for other
combinations is only from uncontrolled studies or case reports. Combination of antidepres‐
sants and benzodiazepines also has positive results from controlled data in the management
of generalized anxiety disorder and social anxiety disorder. Combination of SSRI and atypical
antipsychotics in the treatment of generalized anxiety disorder too has positive evidence from
controlled trials (Bandelow et al., 2008). Although an array of combination, adjuvant, aug‐
mentation strategies are proposed for the treatment of OCD and PTSD, especially treatment
resistance, only augmentation of SSRI with antipsychotics has positive evidence from control‐
led studies (Bandelow et al., 2008). Rest of the evidence is from uncontrolled data. Table 3
shows various combination regimens in the treatment of anxiety disorders with the recom‐
mendation grades.
Diagnosis Combination and Augmentation Treatments Category of Evidence RecommendationGrade
PANIC
DISORDER
1. Antidepressants + Benzodiazepines Full evidence fromcontrolled studies 2
2. SSRIs+TCAs
3. SSRI+Olanzapine
4. SSRI+Pindolol or TCAs
5. Valproate+Clonazepam
Evidence from
uncontrolled studies 4
6. Lithium+Clomipramine Evidence from casereports 4
GAD
1. Antidepressants+ Benzodiazepines Full evidence fromcontrolled studies 2
2. SSRI+atypical antipsychotics (risperidone or
olanzapine)
Limited positive evidence
from controlled studies 3
SOCIAL
PHOBIA
1. Antidepressants+ Benzodiazepines Limited positive evidencefrom controlled studies 3
2. SSRI+Buspirone Evidence fromuncontrolled studies 4
OCD
1. SSRI+antipsychotics(haloperidol, quetiapine,
olanzapine and risperidone)
Limited positive evidence
from controlled studies 3
2. Citalopram+Reboxetine
3. SSRI+Clomipramine
4. Clomipramine+Lithium
Evidence from
uncontrolled studies 4
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Diagnosis Combination and Augmentation Treatments Category of Evidence RecommendationGrade
5. SSRI+Buspirone
6. SSRI+Topiramate
7. Clomipramine+L-tryptophan
8. SSRI+Pindolol+L-tryptophan
PTSD
1. Adjunctive olanzapine or risperidone Limited positive evidencefrom controlled studies 3
2. SSRI+Triiodothyronine
3. Imipramine+Clonidine
Evidence from
uncontrolled studies 4
4. Venlafaxine+Quetiapine
5. SSRI+Gabapentin
Evidence from case
reports 4
Table 3. Categories of evidence and grades of recommendation for anxiety disorders (Adapted from Bandelow et al.
(2008))
6. Schizophrenia
Even on antipsychotic therapy patients with schizophrenia achieving full remission are only
about 30% (Hert et al., 2007). Although clozapine has significantly greater efficacy compared
to other antipsychotics when unresponsive to either typical or an atypical antipsychotic when
used first, its use is associated with significant adverse effects (Kane et al., 1988). Combination
therapy is one of the strategies to manage such unresponsiveness. Polypharmacy therapy in
the treatment of schizophrenia might be either antipsychotics’ combination or an antipsychotic
combined with an agent not used primarily for treatment of psychosis but has an augmentative
effect. It was observed that at baseline, many schizophrenia patients included in the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) trial were on poly-pharmacother‐
apy-4% taking lithium, 15% other mood stabilizers, 38% antidepressants, 22% anxiolytics and
6% two antipsychotics (Chakos et al., 2006).
Mood stabilizers like lithium, carbamazepine and valproate have been used as adjuvants to
antipsychotic treatment in schizophrenia. While randomized trial-based evidence is available
for valproate and carbamazepine, no randomized controlled trials have investigated the effect
of lithium in patients with schizophrenia. Patients receiving lithium augmentation showed
clinically significant response; this significance was however lost when only patients with non
affective symptoms were included (Leucht et al., 2007a). Data based on randomised trials
suggests that there is no conclusive evidence to recommend either valproate or carbamazepine
is useful as an adjunctive therapy in schizophrenia treatment. However in patients with
schizophrenia, positive effects on aggression and tardive dyskinesia with valproate and on
violence and EEG abnormalities with carbamazepine have been found (Leucht et al., 2007b;
Schwarz et al., 2008).
None of the studies investigating the effect of other augmentation strategies like benzodiaze‐
pines, beta-blockers, antidepressants, anti-inflammatory agents, glutamatergic agents, and
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electroconvulsive therapy have been able to demonstrate significant improvement in patients
with schizophrenia (Correll et al., 2009). Correll et al. (2009) identified certain clinical situations
where antipsychotic co-treatment i.e. combining two antipsychotics are superior to antipsy‐
chotic monotherapy. Both acute exacerbations and chronically continuous course, co-starting
second antipsychotic when compared to augmentation and, co-treatment including clozapine
when compared to a strategy not including clozapine, have been found significant improve‐
ments in clinical symptomatology when managed with antipsychotic co-treatment than with
monotherapy. Among the types of combinations: co-treatment with a typical agent and an
atypical agent has been found to be better than a combination of either two typical or atypical
agents. In a recent review, Ballon and Stroup (2013) question the generalizability of these
findings by commenting that these significant effects would disappear with exclusion of
studies from China. We agree to their remark on doubtfulness of replicating the in-vitro model
that presumes modulating the schizophrenia pathophysiology at a receptor level citing the
limitations in conducting proper clinical trials. Moreover, no guidelines suggest comparative
evidence of individual molecules.
Moreover, evidence for efficacy of clozapine augmentation is also currently sparse. Efficacy of
adjunctive AEDs like lamotrigine and topiramate, SSRIs like citalopram and co-treatment with
other antipsychotics like sulpiride is based on single studies, that too with inconsistent findings
(Sommer et al., 2012). Despite their popularity, pharmacological augmentations of clozapine
are yet to be demonstrated to be superior to placebo. However, a recent metaanalysis, supports
clozapine augmentation with amisulpride and aripiprazole, mirtazapine and ethyl eicosapen‐
taenoic acid (Porcelli et al., 2012).
7. Substance use disorders
7.1. Alcohol use disorders
Antipsychotics, especially haloperidol, have been used in combination with a BZD for
treatment of severe agitation in alcohol withdrawal delirium (Mayo-Smith et al. 2004); however
there are no placebo-controlled trials available. Carbamazepine in combination with tiapride
has also been found to be effective in treatment of this condition (Soyka et al., 2006). Although,
minimal amount of evidence is available, antipsychotic treatment in combination with
benzodiazepines is warranted in the treatment of alcohol related psychosis (Soyka et al.,
2011). For relapse prevention, disulfiram is considered a second-line medication that can be
combined with either naltrexone or acamprosate (Soyka et al., 2011). Although positive open
trials are present (Feeney et al. 2006), a recent controlled trial, COMBINE failed to show that
acamprosate is effective in relapse prevention, either alone, or in combination with naltrexone
(Anton et al. 2006). Ait-Daoudet al. (2001) found combination of ondansetron and naltrexone
reduces craving.
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7.2. Opioid use disorders
A combination of naloxone and flumazenil has been shown to be significantly effective in
treating opioid intoxication with additional benzodiazepine use (Megarbane et al., 2010).
Commonly used combination of clonidine and naltrexone has been regarded as safe and
effective for rapid detoxification (Kleber et al. 2007). More importantly, combination of
buprenorphine and naloxone has excellent evidence in the treatment of opioid withdrawal.
Evidence also supports the use of clonidine and lofexidine as adjunctive medications (Soyka
et al., 2011).
8. Epilepsy
Initial treatment of epilepsies is usually a single antiepileptic drug. However in resistant cases,
strategies like alternate monotherapy or polytherapy are suggested. As alternative monother‐
apy is less common because of the limited efficacy and possible side effects of drugs, poly‐
therapy is commonly initiated when monotherapy fails to control seizures (Bauer et al., 1998).
Although there is satisfactory evidence on initial monotherapy, data on long term effectiveness
or subsequent polypharmacy regimens is lacking; more so with older antiepileptic drugs
(AEDs). Trials have shown that adjunctive therapy with newer AEDs (levetiracetam, oxcar‐
bazepine and topiramate) was favorable than when compared to placebo (Wilby et al., 2005).
Costa et al (2011) in a systematic review and meta-analysis of trials comparing a new add-on
antiepileptic drug treatment with placebo or drug, found a relatively small magnitude to allow
a definitive conclusion about which new antiepileptic drug has superior effectiveness.
However these trials are of short duration and often fail to limit inclusion to either partial or
generalised seizures. Adjunctive treatment with benzodiazepines also has a poor fund of
evidence.
9. Child and geriatric populations
One third of pharmacologically treated mentally ill children and adolescents receive poly‐
pharmacy, with a remarkable increase in the number of children receiving two or more
medications in the past decade (McIntyre and Jerell, 2009)
Psychiatric polypharmacy is common in child and adolescent and geriatric population as well.
With a prevalence of multi-class polypharmacy in child and adolescent population to be 19%,
antidepressants are the most commonly co-prescribed drugs followed by attention deficit and
hyperactivity disorder (ADHD) medications, antipsychotics, mood stabilizers and benzodia‐
zepines (Comer et al., 2010). Except for a few open label studies (Kowatch et al., 2003), data
from randomized controlled trials is lacking in this group. Interactions between the various
molecules in childhood disorders are remarkable. While methylphenidate did not improve
symptoms of ADHD compared to placebo in children and adolescents with bipolar disorder
stabilized on aripiprazole, this agent could improve ADHD symptoms in those taking lithium
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and valproate (Zigman and Blier, 2012). Such noteworthy interactions suggest empirical
rational polypharmacy rather than evidence based polypharmacy.
Similar comment on geriatric population also can be made. Psychiatric polypharmacy in this
population is very common (Loyola et al., 2008) and the major reason for such an approach is
the presence of medical comorbidities, where evidence base is intricate to build.
9.1. Dementia
Polypharmacy in the treatment of dementia has some evidence base. The rational is that
combination therapy of drugs with different modes of action might have a synergistic effect
(Ihl et al., 2011). There are randomized controlled trials that investigated the efficacy of
combination of memantine with various cholinesterase inhibitors and galantamine. However,
there is no conclusive evidence as these studies report both positive and negative results
(Dantoine et al., 2006, Ihl et al., 2011, Kornhuber et al., 2009, Porsteinsson et al., 2008). There is
some evidence from uncontrolled open studies on the effect of donepezil and gingko biloba
combination, but negative (Yancheva et al., 2007).
10. Medical comorbidity
Polypharmacy in patients with medical comorbidity is a rule, however, evidence based
pharmacological treatment in such conditions is very scarce, in fact less applicable. One
important reason is that these subjects are not eligible for most clinical trials (Zimmerman et
al., 2002). It is difficult to conduct randomized controlled trials on these subjects as there would
be obvious complicatedness in setting the inclusion and exclusion criteria. It is recommended
that clinicians should opt for individualized or empirical polypharmacy.
11. Individualized rational polypharmacy
Kingsbury et al. (2001) divided rational polypharmacy into two types: validated and empirical.
Validation or evidence base is based on results from controlled trials or meta-analyses. These
results guide treatment presuming homogeneity in the illnesses, which hardly exists. Empir‐
ical rational polypharmacy is more individualized. Hence empirically this classification can
be restated into “standardized” and “individualized” rational polypharmacy. Standardized
rational polypharmacy refers to the validated strategies that have been discussed so far.
Individualized rational polypharmacy is based on a complete evaluation of the index patient-
timing and characterization of various manifestations, a proper evaluation of response to drugs
in other affected family members and conducting mini investigations in the background of
adequate knowledge of pharmacogenomics, receptor profiles and rating of psychopathology.
Clinicians with proper training and motivation only could go ahead with this strategy;
otherwise these tactics would end up in contra-therapeutic polypharmacy.
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12. Causes of irrational polypharmacy and ways to tackle them
Apart from practicing rational polypharmacy, clinicians need to understand various reasons
and ways to tackle irrational polypharmacy. Several different causes of irrational polyphar‐
macy have been identified (Kingsbury et al., 2001):
1. Fear and laziness. Continuing the earlier prescribed drug/s that has/have not shown
improvement along with the later drug after addition of which there is some response;
continuing the drug that was added to ameliorate acute symptoms even after the primary
drug’s later onset of action has begun.
2. Sloppy diagnosis/ overdiagnosis: such as that of schizoaffective for affective symptoms
which could be a part of schizophrenia or for psychotic agitation misdiagnosing it as an
affective manifestation.
3. Improper titration. Mistaking the effect of the second drug to be due to a combination of
both amidst of the cross titration process.
4. Blind adherence to maximum doses. 80% response on ‘x’ dose of a dose (that is considered
maximum according to one particular guideline) is added with another drug (even after
knowing ‘2x’ dose of the first drug could have been tolerated).
5. Inadequate awareness/ blind disbelief on the therapeutic efficacy of psychotherapeutic
strategies
6. Inadequate knowledge or inattention towards receptor profile of the molecules.
7. Adhering to industry sponsored guidelines
8. Magical beliefs/ using methods based on word of mouth.
Apart from these causes, industry driven pressure leading to unethical practice and improper
monitoring of drug compliance are also equally responsible for irrational polypharmacy.
Zigman and Blier (2012) consider pharmacological characteristics like redundancy (two or
more drugs have similar/overlapping mechanism of action), pharmacodynamic and pharma‐
cokinetic interactions also as causes of irrational polypharmacy. Zigman and Blier (2012) also
provide certain strategies to tackle irrational polypharmacy.
Firstly, to consider selectively active or multifunctional medications wherever appropriate.
Two medications selectively active at two different receptors can be chosen when their action
at these receptors is known to improve the clinical condition, whereas two multifunctional
medications having more or less similar profile at the target receptor should be avoided in
combination. Secondly, to consider various pharmacodynamic and pharmacokinetic interac‐
tions of the molecules in use. An acetylcholinesterase inhibitor should be avoided in combi‐
nation with a drug with potent anticholinergic side effects, whereas using a drug in
combination with a cytochrome p450 enzyme inducer reduces the efficacy of the drug and lead
to irrational polypharmacy. Another strategy is to allow for adequate dose and duration before
considering adjunctive or augmentative strategies. Such strategies although scientific, when
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used without the adequate trial of a previous drug, would be labeled irrational. The last
strategy is to regularly reassess the efficacy of the ongoing combination treatment. Moreover,
a trial of tapering one of the drugs in the combination should be given when the response is
adequate and has sustained for a period of time.
Niculescu and Hulvershorn (2010) suggest a personalized tri-dimensional treatment (i.e.,
concurrent treatment of anxiety, mood, and cognitive abnormalities) plus modulation of
environmental factors (e.g., stress). Such an approach involves rational polypharmacy—the
combination of three or more medications, each acting primarily on anxiety, mood, or
cognition, respectively. Depending on the major pathology, one of these medications is used
at a higher dose and the others at lower doses. For example, in schizophrenia, an antipsychotic
may be primary at a higher dose, with an anxiolytic and/or mood stabilizer secondary at lower
doses. Similarly for mood abnormalities such as bipolar disorder, a mood stabilizer at a higher
dose would be the primary approach and an anxiolytic and antipsychotic secondary at lower
doses.
Apart from these measures, thorough evaluation of the patient’s clinical symptoms and
medication history along with assessment of drug compliance is of utmost importance in
managing irrational polypharmacy. Obtaining drug levels where applicable and a thorough
evaluation of reasons for treatment resistance including ruling out general medical causes is
another important action to avoid irrational polypharmacy and provide maximum patient
care.
Although not validated, polypharmacy justification checklist, not only to justify rational
polypharmacy but also to curb irrational polypharmacy, has been generated by Dr. Clif
Tennison, Helen Ross McNabb Center, East Tennessee. It is a 38 item checklist targeting 9
domains (Appendix).
13. Indian context
There is some epidemiological data available on psychiatric polypharmacy from India.
Polypharmacy is common in India and its prevalence rates range from 9-73% (Padmini et al.,
2007; Sawhney et al., 2004). Ramadas et al. (2010) found that antipsychotic polypharmacy is
more related to typical than with atypical agents. However recently, Shrivastava et al. (2012)
found almost 30% of first episode schizophrenia patients receiving more than one atypical
antipsychotic. These studies were limited to a section of geographical area and it would be
difficult to generalize these findings to other parts of India. Indian studies that have compared
the efficacy of rational polypharmacy with mono-therapies are however lacking. However,
the Indian psychiatric society has formulated certain guidelines for combination therapies in
various disorders. Although no direct recommendation is available, various comments are
made on these regimens (Table 4).
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Year Disorder Available evidence for polypharmacy regimens and comments
2005 Schizophrenia
• Combination of intramuscular haloperidol and lorazepam faster response than
haloperidol alone
• Adjunct studies in India – all open
• Adjunctive medications recommended- Lithium carbonate; Antidepressants;
Benzodiazepines; and Anticonvulsants.
• No specific guidelines
2005 Depression
• Major depressive disorder with psychotic features require combined use of
antidepressant and antipsychotic medication especially fluoxetine and olanzapine
combination
• An SSRI combined with a TCA induce rapid antidepressant response
• First strategy for resistant depression- augmentation with Lithium/Thyroid/Buspirone;
next: combination (TCA-SSRI. Bupropion-SSRI) Depression with anxiety: Efficacy of high
potency benzodiazepine like alprazolam and clonazepam in combination with
antidepressants is beneficial
2005 Bipolar disorder
• Valproate plus haloperidol superior antipsychotic alone in reduction of manic symptoms
• Difficulty in assessing benzodiazepine combination due to short treatment durations,
distinguishing specific antimanic effects from nonspecific sedative effects.
• Lithium plus an antipsychotic and valproate plus an antipsychotic suggest greater
efficacy or a more rapid onset of action than with these agents alone
• Combination of divalproex plus an SSRI an effective strategy for management of
breakthrough depression during maintenance of bipolar I disorder
2006 Alcohol usedisorders
• Several animal studies demonstrate combinations of medications e.g. disulfiram
+naltraxone, acamprosate +naltraxone are more effective in reducing alcohol intake than
these drugs used alone
• Myth: Combining more than one treatment method has no advantage.
2006 Nicotine usedirorders
• Combining nicotine patch with either nicotine gum or nicotine nasal spray increases long-
term abstinence rates over those produced by a single form of nicotine replacement therapy
2006 Opioid usedisorders
• In the management of withdrawal, non opioid medications like clonidine,
benzodiazepines, NSAIDs or a combination of these.
• Rapid detoxification: Naloxone in combination with other medications such as clonidine
and benzodiazepines
• Naltrexone with clonidine for rapid detoxification is safe and effective
• Buprenorphine and naloxone combination utilized for agonist maintenance therapy
2007 Elderly anxietydisorders
• Benzodiazepines may be used to reduce the severity of anxiety, the need for rapid
anxiolysis along with SSRIs
• Beta blockers may be used as augmenting agents, especially when somatic symptoms of
anxiety are prominent
• Low dose of a tricyclic antidepressant could be used to treat insomnia associated with
anxiety in patients who are receiving SSRI.
2007 Alzheimer’sdisease
• The use and combinations of pharmacological agents should be decided on a case-by-case
basis.
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Year Disorder Available evidence for polypharmacy regimens and comments
2007 Elderlydepression
• Patients with major depression with psychotic features require combined use of
antidepressant and antipsychotic medications
2007 Psychosis inelderly
• Refractory cases may be tried on a combination of clozapine + Amisulpride.
• Lithium augmentation, citalopram+methylphenidate, modafinil+floxetine or mirtazapine,
dexamethasone plus any antidepressant may be indicated
2008
Depression in
children and
Adolescents
• Recommendation for adults with TRD may be applicable to youth
2008 ADHD • Combined pharmacotherapy only to be used when at least two individual agents (initiallymethylphenidate and dexamphetamine) have failed.
Table 4. Data on polypharmacy regimens in the Indian Psychiatric society treatment guidelines
14. Summary, conclusions and recommendations
• Following the dimensional approach in treating psychiatric disorders, polypharmacy,
specifically, multiclass polypharmacy is very common.
• However, rationality in the approach determines whether the outcome is therapeutic or
contra therapeutic.
• A positive evidence base from controlled trials for polypharmacy is highest for-
• Depression (add on)-mirtazapine in combination with SSRI
• Depression (augment)-SSRI s with atypical antipsychotics/lithium
• Acute mania-there is not enough unambiguous evidence that supports combination therapy
of antipsychotic+mood stabilizer as a general first line treatment.
• Acute bipolar depression-olanzapine+fluoxetine and lamotrigine+lithium
• Bipolar prophylaxis-valproate+lithium, valproate or lithium, with atypical antipsychotics
(aripiprazole, quetiapine, risperidone and ziprasidone).
• Panic disorder-combination of clonazepam plus paroxetine or sertraline.
• Generalized anxiety disorder-combination of antidepressants and benzodiazepines and
combination of SSRI and atypical antipsychotics
• Social anxiety disorder-combination of antidepressants and benzodiazepines
• OCD & PTSD-augmentation of SSRI with antipsychotics
• Schizophrenia-valproate and carbamazepine adjuvant treatment; clozapine augmentation
with amisulpride and aripiprazole, mirtazapine and ethyl eicosapentaenoic acid
• Alcohol withdrawal delirium-haloperidol used in combination with a BZD
Evidence-based Strategies in Herbal Medicine, Psychiatric Disorders and Emergency Medicine86
• Opioid withdrawal-naloxone and flumazenil, buprenorphine and naloxone; rapid detoxi‐
fication-clonidine and naltrexone;
• Focal epilepsies-adjunctive therapy with newer AEDs (levetiracetam, oxcarbazepine and
topiramate)
• It is recommended that clinicians should opt for individualized or empirical polypharmacy
as it is difficult to conduct randomized controlled trials on these subjects because of obvious
complicatedness in setting the inclusion and exclusion criteria and derive/ generalize data
from them.
• Use of polypharmacy justification checklist to justify rational polypharmacy and also to curb
irrational polypharmacy may be an useful option
Abbreviations
• 5HT1A-5-hydroxytryptamine 1A
• ADHD-Attention Deficit and Hyperactivity Disorder
• AED-Anti Epileptic Drug
• BZD-Benzodiazepine
• CATIE-Clinical Antipsychotic Trials of Intervention Effectiveness
• EEG-Electroencephalography
• GSK-Glycogen synthase kinase
• MAO-Monoamine oxidase
• NIMH-National Institute of Mental Health
• NSAID-Non-steroidal anti-inflammatory drug
• OCD-Obsessive Compulsive Disorder
• PTSD-Post Traumatic Stress Disorder
• RCT-Randomized Control Trial
• SAM-S-adenosyl-l-methionine
• SNRI-Serotonin–norepinephrine reuptake inhibitor
• SSRI-selective serotonin reuptake inhibitor
• TCA-Tricyclic Antidepressant
• TRD-Treatment Resistant Depression
• U.S. FDA-The United States Food and Drug Administration
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